An essential component of the translation of the new knowledge generated by the CRE REDUCE will be to test the clinical safety and tolerability of the novel doses that aim to suppress the emergence of resistance.

Previous in vitro studies that have attempted to quantify the relationship between pharmacokinetics and pharmacodynamics and the development of resistance have mostly found that higher antimicrobial exposures are required. Since higher drug exposures lead to concerns for patient safety this multi-centre study will use therapeutic drug monitoring or TDM to optimize antimicrobial exposures and test for the safety and tolerability of the new doses.

Project members

Professor Jason Roberts

Chief Investigator and CRE lead

Dr Peter Hopkins

Chief Investigator

Professor Jeffrey Lipman

Chief Investigator

Professor Gavin Joynt

Chief Investigator

Professor Nick Graves

Associate Investigator

Associate Professor Andrew Udy

Associate Investigator

Associate Professor Daniel Chambers

Associate Investigator